Recital 25, Regulation (EU) 2026/1826

In forcesince 28 Jul 2026

Two applications for the renewal of the approval of the active substance clomazone were submitted on 30 October 2015 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 8 February 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 12 February 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 8 March and 8 May 2023. On 15 April 2019, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 14 and 15 May 2019, respectively, within the deadline given. On 18 February 2020, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605 [Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties (OJ L 101, 20.4.2018, p. 33, ELI: http://data.europa.eu/eli/reg/2018/605/oj).], pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 12 and 16 August, and 31 October 2022, respectively, within the deadline given. The Authority conducted an additional public consultation on the updated draft renewal assessment report between 31 October 2023 and 3 January 2024. On 18 December 2024, the Authority adopted its conclusion and communicated it to the applicants, the Member States and the Commission; it was published on 21 February 2025. The Authority published a revised version of the conclusion on 1 September 2025 to clarify issues related to data gaps identified. The Commission initiated preliminary discussions on the renewal of the approval of the active substance clomazone in the Standing Committee on Plants, Animals, Food and Feed on 11 March 2025. However, in spite of the revised conclusion, some outstanding scientific issues concerning the technical specification of the active substance, effective risk mitigation measures, human exposure and ecotoxicological properties still have to be clarified. The Commission is therefore preparing a new mandate to the Authority. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 15 months, until 31 December 2027.